RemeGen Co., Ltd. (SHA:688331)

RemeGen Statistics

Total Valuation

RemeGen has a market cap or net worth of CNY 47.58 billion. The enterprise value is 48.98 billion.

Market Cap	47.58B
Enterprise Value	48.98B

Important Dates

The next estimated earnings date is Thursday, October 30, 2025.

Earnings Date	Oct 30, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	355.03M
Shares Outstanding	n/a
Shares Change (YoY)	+0.23%
Shares Change (QoQ)	-3.92%
Owned by Insiders (%)	12.28%
Owned by Institutions (%)	59.57%
Float	464.32M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	22.95
PB Ratio	20.18
P/TBV Ratio	21.59
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-43.06
EV / Sales	23.52
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-62.49

Financial Position

The company has a current ratio of 1.06, with a Debt / Equity ratio of 1.13.

Current Ratio	1.06
Quick Ratio	0.74
Debt / Equity	1.13
Debt / EBITDA	n/a
Debt / FCF	-3.41
Interest Coverage	-13.16

Financial Efficiency

Return on equity (ROE) is -45.30% and return on invested capital (ROIC) is -13.42%.

Return on Equity (ROE)	-45.30%
Return on Assets (ROA)	-11.67%
Return on Invested Capital (ROIC)	-13.42%
Return on Capital Employed (ROCE)	-32.81%
Revenue Per Employee	675,263
Profits Per Employee	-370,511
Employee Count	2,999
Asset Turnover	0.36
Inventory Turnover	0.51

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +197.33% in the last 52 weeks. The beta is 0.88, so RemeGen's price volatility has been lower than the market average.

Beta (5Y)	0.88
52-Week Price Change	+197.33%
50-Day Moving Average	92.48
200-Day Moving Average	58.34
Relative Strength Index (RSI)	43.88
Average Volume (20 Days)	8,032,318

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, RemeGen had revenue of CNY 2.07 billion and -1.14 billion in losses. Loss per share was -2.11.

Revenue	2.07B
Gross Profit	1.72B
Operating Income	-1.08B
Pretax Income	-1.14B
Net Income	-1.14B
EBITDA	-837.97M
EBIT	-1.08B
Loss Per Share	-2.11

Balance Sheet

The company has 1.28 billion in cash and 2.67 billion in debt, giving a net cash position of -1.39 billion.

Cash & Cash Equivalents	1.28B
Total Debt	2.67B
Net Cash	-1.39B
Net Cash Per Share	n/a
Equity (Book Value)	2.36B
Book Value Per Share	4.44
Working Capital	150.27M

Cash Flow

In the last 12 months, operating cash flow was -539.67 million and capital expenditures -244.03 million, giving a free cash flow of -783.71 million.

Operating Cash Flow	-539.67M
Capital Expenditures	-244.03M
Free Cash Flow	-783.71M
FCF Per Share	n/a

Margins

Gross margin is 83.07%, with operating and profit margins of -52.27% and -54.87%.

Gross Margin	83.07%
Operating Margin	-52.27%
Pretax Margin	-54.87%
Profit Margin	-54.87%
EBITDA Margin	-40.42%
EBIT Margin	-52.27%
FCF Margin	n/a

Dividends & Yields

RemeGen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.23%
Shareholder Yield	-0.23%
Earnings Yield	-2.39%
FCF Yield	-1.65%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RemeGen has an Altman Z-Score of 1.52 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.52
Piotroski F-Score	4